These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 3286051)

  • 21. Use of bethanechol chloride with phenothiazines: a case report.
    Schubert DS
    Am J Psychiatry; 1979 Jan; 136(1):110-1. PubMed ID: 758813
    [No Abstract]   [Full Text] [Related]  

  • 22. Efficacy of imipramine in psychotic versus nonpsychotic depression.
    Birkenhager TK; van den Broek WW; Mulder PG; Moleman P; Bruijn JA
    J Clin Psychopharmacol; 2008 Apr; 28(2):166-70. PubMed ID: 18344726
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fluphenazine decanoate dose and severity of depression in patients with post-psychotic depression.
    Siris SG; Strahan A; Mandeli J; Cooper TB; Casey E
    Schizophr Res; 1988; 1(1):31-5. PubMed ID: 3154504
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adjunctive imipramine in substance-abusing dysphoric schizophrenic patients.
    Siris SG; Mason SE; Bermanzohn PC; Shuwall MA; Aseniero MA
    Psychopharmacol Bull; 1993; 29(1):127-33. PubMed ID: 8378506
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antidepressant drug therapy in psychotic depression.
    Davidson JR; McLeod MN; Kurland AA; White HL
    Br J Psychiatry; 1977 Nov; 131():493-6. PubMed ID: 338082
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acute extrapyramidal reactions with fluphenazine hydrochloride and fluphenazine decanoate.
    Gelenberg AJ; Doller JC; Schooler NR; Mieske M; Severe J; Mandel MR
    Am J Psychiatry; 1979 Feb; 136(2):217-9. PubMed ID: 367182
    [No Abstract]   [Full Text] [Related]  

  • 27. Protracted vomiting following abrupt cessation of psychotropics: a case report.
    Kalman T; Warner GM
    Can Psychiatr Assoc J; 1978 Apr; 23(3):163-5. PubMed ID: 647615
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The use of antidepressants for negative symptoms in a subset of schizophrenic patients.
    Siris SG; Bermanzohn PC; Gonzalez A; Mason SE; White CV; Shuwall MA
    Psychopharmacol Bull; 1991; 27(3):331-5. PubMed ID: 1775607
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Replacement of chronically administered anticholinergic drugs by amantadine in outpatient management of chronic schizophrenia.
    McEvoy JP; McCue M; Freter S
    Clin Ther; 1987; 9(4):429-33. PubMed ID: 2886223
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
    Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
    J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The initiation of long-term pharmacotherapy in schizophrenia: dosage and side effect comparisons between oral and depot fluphenazine.
    Schooler NR; Levine J
    Pharmakopsychiatr Neuropsychopharmakol; 1976 Jul; 9(4):159-69. PubMed ID: 790413
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic reversal with benxtropine in schizophrenics. Practical and theoretical significance.
    Singh MM; Kay SR
    J Nerv Ment Dis; 1975 Apr; 160(4):258-66. PubMed ID: 1097596
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cholinergic syndrome following anticholinergic withdrawal in a schizophrenic patient abusing marijuana.
    Tandon R; Dutchak D; Greden JF
    Br J Psychiatry; 1989 May; 154():712-4. PubMed ID: 2597866
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A double-blind multicentre trial comparing mianserin with imipramine.
    Pichot P; Dreyfus JF; Pull C
    Br J Clin Pharmacol; 1978; 5 Suppl 1(Suppl 1):87S-90S. PubMed ID: 341950
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Stability of the postpsychotic depression syndrome.
    Siris SG; Rifkin A; Reardon GT; Doddi SR; Strahan A; Hall KS
    J Clin Psychiatry; 1986 Feb; 47(2):86-8. PubMed ID: 3944070
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic effects of imipramine are counteracted by its metabolite, desipramine, in patients with generalized anxiety disorder.
    McLeod DR; Hoehn-Saric R; Porges SW; Kowalski PA; Clark CM
    J Clin Psychopharmacol; 2000 Dec; 20(6):615-21. PubMed ID: 11106132
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Control of bed-wetting with benztropine.
    Costa JF; Sramek J; Bera RB; Brenneman M; Cristobal M
    Am J Psychiatry; 1990 May; 147(5):674. PubMed ID: 2327502
    [No Abstract]   [Full Text] [Related]  

  • 38. Comments on article by Dr Birkenhager et al: "Efficacy of imipramine in psychotic versus nonpsychotic depression".
    Baldessarini RJ
    J Clin Psychopharmacol; 2008 Dec; 28(6):716; author reply 717-8. PubMed ID: 19011451
    [No Abstract]   [Full Text] [Related]  

  • 39. An open clinical trial with the long-acting neuroleptics flupenthixol decanoate and fluphenazine decanoate in the maintenance treatment of schizophrenia.
    Kong DS; Yeo SH
    Pharmatherapeutica; 1989; 5(6):371-9. PubMed ID: 2687894
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Depot fluphenazine decanoate and enanthate for schizophrenia.
    David A; Adams CE; Eisenbruch M; Quraishi S; Rathbone J
    Cochrane Database Syst Rev; 2005 Jan; (1):CD000307. PubMed ID: 15674872
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.